TCGA-85-8354-01A-31R-2326-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 53
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.650
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.530
- MTORC1_SIGNALING+0.490
- MYC_TARGETS_V1+0.490
- UNFOLDED_PROTEIN_RESPONSE+0.380
- OXIDATIVE_PHOSPHORYLATION+0.340
- SPERMATOGENESIS+0.290
- CHOLESTEROL_HOMEOSTASIS+0.270
- GLYCOLYSIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- INTERFERON_GAMMA_RESPONSE-0.470
- IL6_JAK_STAT3_SIGNALING-0.440
- ANGIOGENESIS-0.400
- COMPLEMENT-0.400
- ALLOGRAFT_REJECTION-0.390
- PROTEIN_SECRETION-0.390
- KRAS_SIGNALING_UP-0.380
- TGF_BETA_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.942 |
| 2 | TCGA-56-8304-01A-11R-2326-07 | — | cohortSQ1 | 0.934 |
| 3 | 20020032.TNBC | — | E | 0.925 |
| 4 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.913 |
| 5 | TCGA-58-A46N-01A-11R-A24H-07 | — | cohortSQ2 | 0.911 |
| 6 | TCGA-LA-A446-01A-21R-A24Z-07 | — | cohortSQ2 | 0.911 |
| 7 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.910 |
| 8 | SRR6013549 | — | cohortSQ2 | 0.910 |
| 9 | C3N-02434 | — | cohortSQ2 | 0.910 |
| 10 | C3N-00555 | — | cohortSQ2 | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.650 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |